Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice — ASN Events
  1. Schedule
  2. Posters1
  3. Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice

Risk of chemotherapy-induced febrile neutropenia with early discontinuation of pegfilgrastim prophylaxis in US clinical practice (#256)

Derek Weycker 1 , Xiaoyan Li 2 , Rich Barron 2 , Yanli Li 2 , maureen Reiner 2 , Alex Kartashov 1 , Jacqueline Figueredo 1 , Spiros Tzivelekis 2 , Jacob Garcia 2 , Joel Cohen (Presenter on behalf of investigators) 3
  1. Policy Analysis Inc, Brookline, MA, USA
  2. Amgen Inc., Thousand Oaks, CA, USA
  3. Amgen Australia Pty Ltd, Sydney, NSW, Australia
Publish consent withheld
#COSA2015